Tagrisso

Generic name: osimertinib

Used for: Non-small cell lung cancer with an EGFR gene change

How do you pay?

How to pay the least

Ask for the cash price

Tagrisso

We didn’t find one.

  1. Ask your pharmacy for Tagrisso’s cash price, and one or two other pharmacies too.
  2. Tagrisso’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify AZ&Me Prescription Savings Program. For AZ&Me’s Specialty and Primary products, your annual adjusted gross income must be at or below 300% of the Federal Poverty Level Or call 1-800-292-6363.

See if you qualify 

Compare every option

Question
Brand nameTagrisso
Authorized genericosimertinib
Regular genericosimertinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Tagrisso?
The original
–
–

Brand nameThe maker’s card

TAGRISSO Co-pay Savings Program

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

The card takes up to $26,000 a year off your co-pay.

Sign up on tagrissohcp.com 

Or call 1-844-275-2360.

In the maker’s words

“Most eligible patients will pay as little as $0 per month and may have access to up to $26,000 per year to assist with TAGRISSO out-of-pocket costs…”

From the maker’s offer on tagrissohcp.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Tagrisso itself, from the same company, sold without the brand name, and usually for less. For now Tagrisso is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TAGRISSO is a kinase inhibitor indicated for:

  • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
  • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
  • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
  • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
  • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.

Source: the FDA label for Tagrisso (AstraZeneca Pharmaceuticals LP), September 14, 2026. Full label on DailyMed 

Good to know

Prices checked October 27, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tagrisso/